The impact of 2nd-line treatment (tx) after 1st-line Gemcitabine plus Nab-paclitaxel (GemNab) in advanced pancreatic cancer (APC) patients (pts).

Brunella Di Stefano,Maria Bensi,Cinzia Bagalà,Alexia Spring,Marta Chiaravalli,Marta Ribelli,Maria Grazia Maratta,Floriana Camarda,Giampaolo Tortora,Lisa Salvatore

The impact of 2nd-line treatment (tx) after 1st-line Gemcitabine plus Nab-paclitaxel (GemNab) in advanced pancreatic cancer (APC) patients (pts).

2020

Brunella Di Stefano
Maria Bensi
Cinzia Bagalà
Alexia Spring
Marta Chiaravalli
Marta Ribelli
Maria Grazia Maratta
Floriana Camarda
Giampaolo Tortora
Lisa Salvatore

e16759Background: Three main phase III randomized studies investigated the role of 2nd-line tx in APC pts. The PANCREOX study failed to demonstrate a survival advantage of mFOLFOX vs 5FU/LV. Conver...

Keywords:

Oncology
Internal medicine
Gemcitabine
Pathology
Nab-paclitaxel
Pancreatic cancer
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations